Anmelden Kostenlos registrieren

Acelrx Pharmaceuticals Inc Schwankungsanfälligkeit

Was ist das Schwankungsanfälligkeit von Acelrx Pharmaceuticals Inc?

Schwankungsanfälligkeit von Acelrx Pharmaceuticals Inc ist 11.23%

Was ist die Definition von Schwankungsanfälligkeit?

Die Schwankungsanfälligkeit oder Prozent des durchschnittlichen wahren Bereichs (ATRP 14) ist die ATR, ausgedrückt als Prozentsatz des Schlusskurses.

Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.

The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.

Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets

Schwankungsanfälligkeit von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acelrx Pharmaceuticals Inc

Was macht Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Unternehmen mit schwankungsanfälligkeit ähnlich Acelrx Pharmaceuticals Inc